Fresenius Kabi Stymied in Patent Dispute, Delays Generic Nausea Drug Release by a Decade

In a recent legal development, Fresenius Kabi USA LLC has faced a setback in its efforts to introduce a generic version of a nausea drug. The Delaware federal court ruled against Fresenius’ invalidity arguments concerning two patents held by Heron Therapeutics. As a result, Fresenius may be prevented from bringing its generic drug to market for approximately ten years. The case underscores ongoing challenges in the pharmaceutical industry related to patent disputes and generic drug competition. Further details on this legal dispute can be found in Law360’s coverage here.